The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation

Biomaterials

Volumn 31, Issue 25, 2010, Pages 6597-6611

  Mohanty, Chandana ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Apoptosis; Bioavailability; Cancer therapy; Curcumin; Nanoparticle

Indexed keywords

AKT ACTIVATION; ALKALINE PH; ANTICANCER DRUG; APOPTOSIS; AQUEOUS MEDIUM; AQUEOUS SOLVENTS; CANCER CELL LINES; CANCER THERAPY; CELL VIABILITY; CELLULAR UPTAKE; CURCUMIN; DELIVERY SYSTEMS; ENHANCED STABILITY; IN-VITRO; IN-VIVO; MALIGNANT TUMORS; MOLECULAR BASIS; NANO PARTICULATES; NARROW SIZE DISTRIBUTIONS; NUCLEAR FACTOR KAPPAB; OPTIMUM POTENTIAL; PHOSPHATE BUFFER SALINES; REGULATED GENES; TISSUE ABSORPTION; WESTERN BLOTTING;

ACTIVATION ANALYSIS; BIOCHEMISTRY; BIOCOMPATIBILITY; CELL CULTURE; GENE EXPRESSION; NANOPARTICLES; ONCOLOGY; PHARMACOKINETICS; SYSTEM STABILITY;

CELL DEATH;

CUR 500; CURCUMIN; CYCLIN D; GLYCEROL OLEATE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; POLOXAMER; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; WATER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; CELL ASSAY; CELL PROLIFERATION; COLONY FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY TEST; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; NEOPLASMS; SOLUBILITY; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DRUG STABILITY; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; SOLUBILITY; WATER;

MUS;

EID: 77953958625     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.04.062     Document Type: Article

References (50)

1. Das M., Mohanty C., Sahoo S.K. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009, 6(3):285-304.
2. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8(24):1112-1120.
3. Sahoo S.K., Parveen S., Panda J. The present and future of nanotechnology in human health care. Nanomedicine 2007, 3(1):20-31.
4. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., Aggarwal B.B. Curcumin and cancer: an " old-age" disease with an " age-old" solution. Cancer Lett 2008, 267(1):133-164.
5. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23(1A):363-398.
6. Fryer R.A., Galustian C., Dalgelish A.G. Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol 2009, 4(2):102-112.
7. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30(2):85-94.
8. Ammon H.P., Wahl M.A. Pharmacology of Curcuma longa. Planta Med 1991, 57(1):1-7.
9. Hsu C.H., Cheng A.L. Clinical studies with curcumin. Adv Exp Med Biol 2007, 595:471-480.
10. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21(4B):2895-2900.
11. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4(6):807-818.
12. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010, 79(3):330-338.
13. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., et al. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin" ): a novel strategy for human cancer therapy. J Nanobiotechnol 2007, 5:3.
14. Maiti K., Mukherjee K., Gantait A., Saha B.P., Mukherjee P.K. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007, 330(1-2):155-163.
15. Preetha A., Banerjee R., Huilgol N. Tensiometric profiles and their modulation by cholesterol: implications in cervical cancer. Cancer Invest 2007, 25(3):172-181.
16. Suresh D., Srinivasan K. Studies on the in vitro absorption of spice principles - curcumin, capsaicin and piperine in rat intestines. Food Chem Toxicol 2007, 45(8):1437-1442.
17. Tiyaboonchai W., Tungpradit W., Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007, 337(1-2):299-306.
18. Shaikh J., Ankola D.D., Beniwal V., Singh D., Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009, 37(3-4):223-230.
19. Mohanty C., Acharya S., Mohanty A.K., Dilnawaz F., Sahoo S.K. Curcumin encapsulated MePEG/PCL block copolymeric micelles: A novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond) 2010, 5(3):433-449.
20. Trickler W.J., Nagvekar A.A., Dash A.K. A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech 2008, 9(2):486-493.
21. Trickler W.J., Nagvekar A.A., Dash A.K. The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel. Pharm Res 2009, 26(8):1963-1973.
22. Wyatt D.M., Dorschel D. A cubic-phase delivery system composed of glyceryl monooleate and water for sustained release of water-soluble drugs. Pharm Tech 1992, October:116.
23. Barakat N.S. Magnetically modulated nanosystems: a unique drug-delivery platform. Nanomedicine 2009, 4(7):799-812.
24. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30(29):5737-5750.
25. Misra R., Acharya S., Dilnawaz F., Sahoo S.K. Sustained antibacterial activity of doxycycline-loaded poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine 2009, 4(5):519-530.
26. Mu L., Seow P., Ngo A., Shen F. Study on surfactant coating of polymeric nanoparticles for controlled delivery of anticancer drug. Colloid Polym Sci 2004, 283(1):58-65.
27. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002, 54(5):759-779.
28. Sahu A., Bora U., Kasoju N., Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008, 4(6):1752-1761.
29. Hafeli U.O., Riffle J.S., Harris-Shekhawat L., Carmichael-Baranauskas A., Mark F., Dailey J.P., et al. Cell uptake and in vitro toxicity of magnetic nanoparticles suitable for drug delivery. Mol Pharm 2009, 6(5):1417-1428.
30. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31(13):3694-706.
31. Zhang S., Chen X., Gu C. The effect of iron oxide magnetic nanoparticles on smooth muscle cells. Nanoscale Res Lett 2008, 4(1):70-77.
32. Kunwar A., Barik A., Mishra B., Rathinasamy K., Pandey R., Priyadarsini K.I. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 2008, 1780(4):673-679.
33. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004, 112(2):335-340.
34. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly(d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002, 82(1):105-114.
35. Pan C.J., Tang J.J., Shao Z.Y., Wang J., Huang N. Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin. Colloids Surf B Biointerfaces 2007, 59(1):105-111.
36. Ma Z., Haddadi A., Molavi O., Lavasanifar A., Lai R., Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008, 86(2):300-310.
37. Sahu A., Kasoju N., Bora U. Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules 2008, 9(10):2905-2912.
38. Lev-Ari S., Vexler A., Starr A., Ashkenazy-Voghera M., Greif J., Aderka D., et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007, 25(6):411-418.
39. Lev-Ari S., Strier L., Kazanov D., Elkayam O., Lichtenberg D., Caspi D., et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 2006, 45(2):171-177.
40. Aggarwal S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006, 69(1):195-206.
41. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005, 11(20):7490-7498.
42. Siwak D.R., Shishodia S., Aggarwal B.B., Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005, 104(4):879-890.
43. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15(12):1867-1876.
44. Lai J., Chen J., Lu Y., Sun J., Hu F., Yin Z., et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech 2009, 10(3):960-966.
45. Wyllie A.H., Kerr J.F., Currie A.R. Cell death: the significance of apoptosis. Int Rev Cytol 1980, 68:251-306.
46. Ganta S., Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6(3):928-939.
47. Goel A., Boland C.R., Chauhan D.P. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001, 172(2):111-118.
48. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003, 89(11):2110-2115.
49. Ma Z., Shayeganpour A., Brocks D.R., Lavasanifar A., Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr 2007, 21(5):546-552.
50. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007, 60(2):171-177.